Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

The Changing Treatment Landscape in MCL and CLL: A Review of Standards of Care

September 28th 2018

Among the many new developments in B-cell lymphoma in recent years, the inhibition of Bruton tyrosine kinase represents a particularly notable achievement.

Dr. Wang on Managing AEs Related to BTK Inhibitors

September 27th 2018

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses how to manage adverse events related to BTK inhibitors in the treatment of mantle cell lymphoma.

Dr. Shah on Treatment of Patients with p53-Mutated MCL

September 20th 2018

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses the treatment of patients with p53-mutated mantle cell lymphoma.

Dr. Cohen Discusses the Treatment of MCL

September 19th 2018

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the treatment of patients with mantle cell lymphoma.

Asymptomatic, Young Patients With MCL May Avoid Active Treatment

September 15th 2018

Frontline therapy may be able to be avoided in asymptomatic, young, fit patients with mantle cell lymphoma.

Dr. Shah Compares Toxicity Profiles of Ibrutinib and Acalabrutinib

September 11th 2018

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, compares toxicity profiles of ibrutinib and acalabrutinib.

One-Size-Fits-All Approach Not Applicable in MCL

September 7th 2018

Bijal D. Shah, MD, discussed the challenge of treating this highly heterogeneous disease, how to choose the optimal treatment regimen, and the ongoing role of BTK inhibitors.

Dr. Eyre on BTK Inhibitors in Combination With Venetoclax for MCL

September 7th 2018

Toby Eyre, MBChB, MRCP, consultant hematologist at Oxford University Hospitals NHS Trust, discusses the potential for BTK inhibitors to be used in combination with venetoclax for mantle cell lymphoma.

Dr. Shah Compares BTK Inhibitors for Mantle Cell Lymphoma

September 6th 2018

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, compares the 2 available BTK inhibitors for patients with mantle cell lymphoma.

Dr. Goy on Immunotherapy in Mantle Cell Lymphoma

September 5th 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the potential of immunotherapy in patients with mantle cell lymphoma (MCL).

Next Steps in MCL Include Frontline Trials of BTK Inhibitors

September 5th 2018

Simon Rule, MD, PhD, discusses the current and potential use of BTK inhibitors for the treatment of patients with mantle cell lymphoma.

Dr. Kahl Discusses Unmet Needs in MCL

August 28th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses unmet needs in the treatment landscape of mantle cell lymphoma.

Deferred Treatment Beneficial in Some Patients With MCL

August 24th 2018

Jonathon B. Cohen, MD, discusses the potential benefit of offering deferred therapy to asymptomatic patients with mantle cell lymphoma.

Potency of CAR T-Cell Therapy Investigated in Relapsed/Refractory MCL

August 22nd 2018

Axicabtagene ciloleucel (axi-cel; Yescarta) is being evaluated in patients with relapsed or refractory mantle cell lymphoma—a rare B-cell non-Hodgkin lymphoma that contributes 4200 new patients in the United States each year.

Kahl Looks Toward the Future in MCL

August 13th 2018

Brad Kahl, MD, discusses the exciting new advancements on the horizon for the treatment of patients with mantle cell lymphoma.

Goy Discusses Maintenance, CAR T-Cell Therapy in MCL

August 10th 2018

Andre Goy, MD, shares insight on the new array of treatment options for mantle cell lymphoma and how to properly implement them.

Dr. Eyre on Results of Venetoclax in Relapsed/Refractory MCL

August 9th 2018

Toby Eyre, MBChB, MRCP, consultant hematologist at Oxford University Hospitals NHS Trust, discusses the results of single-agent venetoclax (Venclexta) in patients with relapsed/refractory mantle cell lymphoma.

Dr. Goy on the Combination of Biological Therapies in Relapsed MCL

August 3rd 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the combination of biological therapies in the treatment of patients with relapsed mantle cell lymphoma (MCL).

Dr. Kahl on the Potential of CAR T-Cell Therapy in MCL

August 3rd 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in mantle cell lymphoma (MCL).

Dr. Goy on the Evolution of Treatment in Mantle Cell Lymphoma

July 26th 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the evolution of treatment in mantle cell lymphoma (MCL).